Literature DB >> 10933661

Plasma, urine and skin pharmacokinetics of cefepime in burns patients.

E Sampol1, A Jacquet, M Viggiano, V Bernini, J C Manelli, B Lacarelle, A Durand.   

Abstract

We studied the pharmacokinetics of cefepime (2 g bd) in six burns patients. Blood, urine and skin samples were collected to measure cefepime concentrations. A two-compartment model was fitted to the data. At day 1, t(1/2beta) was 2.45 +/- 0.56 h, V(ss) 0.36 +/- 0.1 L/kg, total clearance 152 +/- 25.2 mL/min, and AUC 217 +/- 34 mg*h/L. There was no statistical difference between day 1 and day 3 for any of the pharmacokinetic parameters. We demonstrated good penetration of cefepime in skin. These results show that it is not necessary to change the standard dosage of cefepime in burns patients.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10933661     DOI: 10.1093/jac/46.2.315

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  8 in total

Review 1.  Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability.

Authors:  Federico Pea; Pierluigi Viale; Mario Furlanut
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

2.  Adequacy of high-dose cefepime regimen in febrile neutropenic patients with hematological malignancies.

Authors:  Fekade Bruck Sime; Michael S Roberts; Ing Soo Tiong; Julia H Gardner; Sheila Lehman; Sandra L Peake; Uwe Hahn; Morgyn S Warner; Jason A Roberts
Journal:  Antimicrob Agents Chemother       Date:  2015-06-29       Impact factor: 5.191

Review 3.  Clinical Pharmacokinetics and Pharmacodynamics of Cefepime.

Authors:  Gwendolyn M Pais; Jack Chang; Erin F Barreto; Gideon Stitt; Kevin J Downes; Mohammad H Alshaer; Emily Lesnicki; Vaidehi Panchal; Maria Bruzzone; Argyle V Bumanglag; Sara N Burke; Marc H Scheetz
Journal:  Clin Pharmacokinet       Date:  2022-06-29       Impact factor: 5.577

Review 4.  Cefepime: a reappraisal in an era of increasing antimicrobial resistance.

Authors:  Andrea Endimiani; Federico Perez; Robert A Bonomo
Journal:  Expert Rev Anti Infect Ther       Date:  2008-12       Impact factor: 5.091

5.  Prospective monitoring of cefepime in intensive care unit adult patients.

Authors:  Thomas M Chapuis; Eric Giannoni; Paul A Majcherczyk; René Chioléro; Marie-Denise Schaller; Mette M Berger; Saskia Bolay; Laurent A Décosterd; Denis Bugnon; Philippe Moreillon
Journal:  Crit Care       Date:  2010-04-01       Impact factor: 9.097

Review 6.  Influence of burns on pharmacokinetics and pharmacodynamics of drugs used in the care of burn patients.

Authors:  Benoit Blanchet; Vincent Jullien; Christophe Vinsonneau; Michel Tod
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

Review 7.  Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of β-lactams.

Authors:  Joao Gonçalves-Pereira; Pedro Póvoa
Journal:  Crit Care       Date:  2011-09-13       Impact factor: 9.097

8.  Pharmacokinetics and Pharmacodynamics of Cefepime in Adults with Hematological Malignancies and Febrile Neutropenia after Chemotherapy.

Authors:  José C Álvarez; Sonia I Cuervo; Edelberto Silva; Jorge A Díaz; Lorena L Jiménez; Daniel S Parra; Julio C Gómez; Ricardo Sánchez; Jorge A Cortés
Journal:  Antibiotics (Basel)       Date:  2021-04-29
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.